健帆生物(300529.SZ)漲4% 發佈新一期股權激勵計劃
格隆匯11月5日丨繼昨日漲停後,健帆生物(300529.SZ)今日繼續上漲,現報80.11元,漲3.96%,暫成交5.35億元,最新總市值336億元。公司昨日發佈2019年第二期股票期權激勵計劃(草案):擬向509名激勵對象授予439.55萬份股票期權,約佔公司總股本的1.05%,行權價格為70.08元/股;業績考核指標為:以2019年扣除非經常性損益後歸屬於上市公司股東的淨利潤為基數,2022年扣除非經常性損益後歸屬於上市公司股東的淨利潤增長率不低於110%。方正證券稱,此次股權激勵計劃激勵對象主要為公司中層管理人員和核心骨幹,能有效吸引和留住優秀人才,進一步調動公司管理層的積極性,保障公司未來持續健康發展。與之前三次股權激勵考核營業收入不同,此次以扣非淨利潤為業績考核指標,2022年業績相比2019年增長不低於110%,即未來三年複合增長率不低於28%,高標準的考核目標彰顯公司管理層對未來業務發展的雄心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.